S A Curley

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?
    Steven A Curley
    Ann Surg Oncol 15:11-3. 2008
  2. ncbi Radiofrequency ablation of hepatocellular carcinoma
    S A Curley
    M D Anderson Cancer Center, University of Texas, Houston, Texas, USA
    Minerva Chir 57:165-76. 2002
  3. ncbi Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Exp Ther Oncol 7:313-26. 2008
  4. ncbi Surgical treatment of colorectal cancer metastasis
    Steven A Curley
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center Houston, Texas, USA
    Cancer Metastasis Rev 23:165-82. 2004
  5. ncbi Radiofrequency ablation of primary and metastatic hepatic malignancies
    Steven A Curley
    Department of Surgical Oncology, Box 444, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Boulevard, Houston, TX 777030, USA
    Int J Clin Oncol 7:72-81. 2002
  6. ncbi Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Ann Surg 239:450-8. 2004
  7. ncbi Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells
    Christopher J Gannon
    Department of Surgical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, Texas, USA
    J Nanobiotechnology 6:2. 2008
  8. ncbi Radiofrequency ablation of malignant liver tumors
    Steven A Curley
    The University of Texas M D Anderson Cancer Center, Department of Surgical Oncology, Box 444, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Ann Surg Oncol 10:338-47. 2003
  9. ncbi Outcomes after surgical treatment of colorectal cancer liver metastases
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Semin Oncol 32:S109-11. 2005
  10. ncbi Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis
    S A Curley
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 232:381-91. 2000

Detail Information

Publications93

  1. ncbi Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?
    Steven A Curley
    Ann Surg Oncol 15:11-3. 2008
  2. ncbi Radiofrequency ablation of hepatocellular carcinoma
    S A Curley
    M D Anderson Cancer Center, University of Texas, Houston, Texas, USA
    Minerva Chir 57:165-76. 2002
    ..0 cm in diameter. Effective treatment of larger tumors awaits the development of more powerful, larger array monopolar and bipolar RFA technologies...
  3. ncbi Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Exp Ther Oncol 7:313-26. 2008
    ..Conjugation of cancer cell-directed targeting agents to gold nanoparticles may represent an effective and cancer-specific therapy to treat numerous types of human malignant disease using noninvasive RF hyperthermia...
  4. ncbi Surgical treatment of colorectal cancer metastasis
    Steven A Curley
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center Houston, Texas, USA
    Cancer Metastasis Rev 23:165-82. 2004
    ..Modern surgical treatment of colorectal liver metastases can be performed safely with low mortality and transfusion rates, and surgical treatment should be considered in patients with disease confined to their liver...
  5. ncbi Radiofrequency ablation of primary and metastatic hepatic malignancies
    Steven A Curley
    Department of Surgical Oncology, Box 444, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Boulevard, Houston, TX 777030, USA
    Int J Clin Oncol 7:72-81. 2002
    ..0 cm in diameter. Effective treatment of larger tumors awaits the development of more powerful, larger array monopolar and bipolar RFA technologies...
  6. ncbi Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Ann Surg 239:450-8. 2004
    ..We performed this prospective analysis to determine early (within 30 days) and late (more than 30 days after) complication rates associated with hepatic tumor RFA...
  7. ncbi Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells
    Christopher J Gannon
    Department of Surgical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, Texas, USA
    J Nanobiotechnology 6:2. 2008
    ..abstract:..
  8. ncbi Radiofrequency ablation of malignant liver tumors
    Steven A Curley
    The University of Texas M D Anderson Cancer Center, Department of Surgical Oncology, Box 444, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Ann Surg Oncol 10:338-47. 2003
    ..Radiofrequency ablation (RFA) is being used to treat primary and metastatic liver tumors. The indications, treatment planning, and limitations of hepatic RFA must be defined and refined by surgeons treating hepatic malignancies...
  9. ncbi Outcomes after surgical treatment of colorectal cancer liver metastases
    Steven A Curley
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Semin Oncol 32:S109-11. 2005
    ..Surgical resection and ablation should be considered as part of a multimodality therapeutic approach to both primary and secondary hepatic malignancies...
  10. ncbi Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis
    S A Curley
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 232:381-91. 2000
    ..To determine the treatment efficacy, safety, local tumor control, and complications related to radiofrequency ablation (RFA) in patients with cirrhosis and unresectable hepatocellular carcinoma (HCC)...
  11. ncbi Regression of hepatocellular cancer in a patient treated with arginine deiminase
    Steven A Curley
    Department of Surgical Oncology, M D Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Box 444, Houston, Texas 77030 4095, USA
    Hepatogastroenterology 50:1214-6. 2003
    ..The results in a single patient with unresectable hepatocellular cancer treated with ADI-PEG20,000 mw suggests this may be a promising, low-toxicity treatment. Full-scale clinical trials have been initiated...
  12. ncbi Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
    Eddie K Abdalla
    Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    Ann Surg 239:818-25; discussion 825-7. 2004
    ..RFA alone or in combination with resection for unresectable patients does not provide survival comparable to resection, and provides survival only slightly superior to nonsurgical treatment...
  13. ncbi Advances in the treatment of liver tumors
    Steven A Curley
    The University of Texas M.D. Anderson Cancer Center, Houston, USA
    Curr Probl Surg 39:449-571. 2002
  14. ncbi Hepatectomy for recurrent colorectal liver metastases after radiofrequency ablation
    A Brouquet
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Br J Surg 98:1003-9. 2011
    ..The results of surgery for recurrent colorectal liver metastases (CLM) after radiofrequency ablation (RFA) have not been evaluated...
  15. ncbi Debunking dogma: surgery for four or more colorectal liver metastases is justified
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Gastrointest Surg 10:240-8. 2006
    ..Certain clinicopathologic factors, including lack of response to neoadjuvant chemotherapy, were associated with a worse prognosis...
  16. ncbi Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  17. ncbi Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma
    Evan S Glazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:2220-6. 2010
    ..This study's purpose was to evaluate the effects of pegylated arginine deiminase (ADI) in terms of toxicity, tumor response, alpha-fetoprotein (AFP) levels, and serum arginine levels...
  18. ncbi Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma
    Yehuda Z Patt
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:578-86. 2004
    ..The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma...
  19. ncbi Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Am Coll Surg 210:934-41. 2010
    ..An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection. The optimal treatment sequence in these patients has not been defined...
  20. ncbi Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma
    M M Bilimoria
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 106, Houston, TX 77030, USA
    Arch Surg 136:528-35. 2001
    ..A subset of patients can be identified who will survive without recurrence beyond 5 years after hepatic resection for hepatocellular carcinoma (HCC)...
  21. ncbi Ablative techniques for hepatocellular carcinoma
    C C Barnett
    University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
    Semin Oncol 28:487-96. 2001
    ..This review will discuss the indications, anticipated benefits, and limitations of current ablative techniques and place these procedures in proper perspective as options for patients with HCC...
  22. ncbi Solitary colorectal liver metastasis: resection determines outcome
    Thomas A Aloia
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77230-1402, USA
    Arch Surg 141:460-6; discussion 466-7. 2006
    ..Every method should be considered to achieve resection of solitary colorectal liver metastasis, including referral to a specialty center, extended hepatectomy, and chemotherapy...
  23. ncbi Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients
    Timothy M Pawlik
    Department of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:1059-69. 2003
    ..85, P =.04). CONCLUSIONS: Resection combined with RFA provides a surgical option to a group of patients with liver metastases who traditionally are unresectable, and may increase long-term survival...
  24. ncbi Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles
    Evan S Glazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:3285-93. 2010
    ..Quantum dots are fluorescent semiconducting nanoparticles that were hypothesized to induce similar injury after radiofrequency field irradiation...
  25. ncbi Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies
    Courtney L Scaife
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030, USA
    Surg Oncol Clin N Am 12:243-55. 2003
    ..Improved technology and concurrent application of RFA with other treatment modalities should continue to improve tumor response and patient survival for patients with unresectable hepatic malignancies...
  26. ncbi Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer
    Courtney L Scaife
    Departments of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:348-54. 2003
    ..The high rate of disease recurrence in our patients indicates that novel combinations of regional and systemic therapies are needed to improve patient outcomes...
  27. ncbi Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles
    Evan S Glazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Surgery 148:319-24. 2010
    ..Solid gold nanoparticles are delivered to cancer cells via conjugation with targeting antibodies. Here, 20-nm gold particles were conjugated to cetuximab, which is an epidermal growth factor receptor-1 (EGFR-1) antibody...
  28. ncbi New trends in the surgical treatment of colorectal cancer liver metastases
    S A Curley
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Tumori 84:281-8. 1998
    ....
  29. ncbi Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT
    S Phongkitkarun
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Radiol 60:700-9. 2005
    ....
  30. ncbi Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma
    S A Ahmad
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    J Gastrointest Surg 5:468-76. 2001
    ..Patients with positive serology for hepatitis B or C undergoing resection for hepatocellular carcinoma have a trend toward worse overall prognosis and a significantly decreased LDFS when compared to patients with negative serology...
  31. ncbi The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors
    Christopher J Gannon
    Department of Surgical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77230-1402, USA
    Semin Radiat Oncol 15:265-72. 2005
    ..This review focuses on the indications, anticipated benefits, and limitations of these ablative techniques...
  32. ncbi Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    J Gastrointest Surg 8:794-804; discussion 804-5. 2004
    ..The prognosis after resection of HCC is influenced by tumor factors and liver disease, but not by HBV or HCV infection. The treatment for HCC should be dictated by the extent of underlying liver disease rather than by hepatitis serology...
  33. ncbi Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 241:715-22, discussion 722-4. 2005
    ..A predicted margin of <1 cm after resection of hepatic colorectal metastases should not be used as an exclusion criterion for resection...
  34. ncbi Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases
    Daria Zorzi
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    J Gastrointest Surg 10:86-94. 2006
    ..AR is not superior to WR in terms of tumor clearance, pattern of recurrence, or survival. WR should remain an integral component of the surgical treatment of CLM...
  35. ncbi Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
    Yun Shin Chun
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    JAMA 302:2338-44. 2009
    ....
  36. ncbi Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization
    Eddie K Abdalla
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Surg 137:675-80; discussion 680-1. 2002
    ..CONCLUSION: Portal vein embolization enables safe and potentially curative extended hepatectomy in a subset of patients who would otherwise be marginal candidates for resection based on a small liver remnant size...
  37. ncbi Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation
    Nestor F Esnaola
    Department of Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA
    J Gastrointest Surg 6:224-32; discussion 232. 2002
    ..3; 95% CI, 2.0 to 19.9). Tumor size and grade are strong predictors of microvascular invasion. A tumor biopsy with pathologic grading at the time of pretransplantation ablative therapy could improve selection of patients with HCC for OLT...
  38. ncbi Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases
    Susan B Kesmodel
    Department of Surgical Oncology, Cancer Biology, Biostatistics, and Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5254-60. 2008
    ..We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases...
  39. ncbi Radiofrequency ablation of malignant liver tumors
    S A Curley
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Oncologist 6:14-23. 2001
    ..0 cm in diameter. Effective treatment of larger tumors awaits the development of more powerful, larger array monopolar and bipolar RFA technologies...
  40. ncbi Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1
    Evan S Glazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Surgery 148:310-8. 2010
    ..The purpose of this study was to investigate cancer cell death using a significantly more active, cobalt-substituted bioengineered arginase...
  41. ncbi Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:1938-46. 2010
    ..This objective of the current study was to determine the association between HCC risk and diabetes duration and type of diabetes treatment...
  42. ncbi The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Hepatol 50:334-41. 2009
    ..The study aimed at addressing the connection between positive family history of liver cancer and hepatocellular carcinoma (HCC) development in the USA...
  43. ncbi Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection
    Dario Ribero
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030-4009, USA
    Ann Surg Oncol 15:986-92. 2008
  44. ncbi Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
    Jean Nicolas Vauthey
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:2065-72. 2006
    ..Chemotherapy before resection of hepatic colorectal metastases (CRM) may cause hepatic injury and affect postoperative outcome...
  45. ncbi Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases
    Evan S Glazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Arch Surg 145:340-5; discussion 345. 2010
    ..The role of positron emission tomography (PET) for patients undergoing chemotherapy remains unclear. We hypothesize that recent chemotherapy treatment could result in false-negative PET results...
  46. ncbi Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
    Edward H Lin
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 29:232-9. 2006
    ..COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib...
  47. ncbi Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Arch Surg 141:537-43; discussion 543-4. 2006
    ..Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival...
  48. ncbi Two-surgeon technique of parenchymal transection contributes to reduced transfusion rate in patients undergoing major hepatectomy: analysis of 1,557 consecutive liver resections
    Martin Palavecino
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Surgery 147:40-8. 2010
    ..Data on factors affecting blood transfusions in large series of liver resection are limited. The aim of this study was to evaluate factors predictive of blood transfusion in hepatectomies performed at a tertiary referral center...
  49. ncbi Resection of hepatic colorectal metastases involving the caudate lobe: perioperative outcome and survival
    Eddie K Abdalla
    Department of Surgical Oncology Unit 444, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    J Gastrointest Surg 11:66-72. 2007
    ..To examine clinical features and outcome of patients who underwent hepatic resection for colorectal liver metastases (LM) involving the caudate lobe...
  50. ncbi Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver
    Luis H Camacho
    Phase I Program, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2190-6. 2007
    ..Systemic paclitaxel is safe and has demonstrated good antitumor activity against breast carcinoma. The objective of this prospective study was to determine the safety and antitumor activity of hepatic intra-arterial paclitaxel therapy...
  51. ncbi High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 29:1083-90. 2011
    ..The impact of complete resection in this well-selected group is controversial...
  52. ncbi Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 123:1883-91. 2008
    ..Controlling for smoking exposure might be a prudent approach to the prevention of HCC, especially in patients with chronic viral hepatitis infections...
  53. ncbi Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    Dario Ribero
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2761-7. 2007
    ..The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology...
  54. ncbi Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hepatology 49:1563-70. 2009
    ..Experimental investigations are necessary for thorough assessment of the relationship between thyroid disorders and HCC...
  55. ncbi Pain and quality of life after treatment in patients with locally recurrent rectal cancer
    Nestor F Esnaola
    Department of Surgery, Pain Research Group, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    J Clin Oncol 20:4361-7. 2002
    ..The purpose of this study was to assess the prevalence of posttreatment pain and QOL of patients with LRRC treated with nonsurgical palliation or resection and identify predictors of poor outcome...
  56. ncbi Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy
    Alexander A Parikh
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Gastrointest Surg 7:1082-8. 2003
    ..It may therefore provide a better therapeutic option, particularly in patients with multiple colorectal metastases...
  57. ncbi Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan
    Nestor F Esnaola
    Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 238:711-9. 2003
    ..Future studies should account for histopathologic differences using uniform criteria to allow better comparison of results...
  58. ncbi Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study
    Timothy M Pawlik
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Surgery 137:403-10. 2005
    ..Patients with HCC and major vascular invasion who derive long-term benefit from resection have no or minimal underlying fibrosis...
  59. ncbi Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma
    Yehuda Z Patt
    Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 21:421-7. 2003
    ..Patients and..
  60. ncbi Ethical issues in surgical palliative care: am I killing the patient by "letting him go"?
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Unit 444, P O Box 301402, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Surg Clin North Am 85:273-86, vii. 2005
    ..An ethics of death and dying requires that the intent and the action of the moral agent be considered...
  61. ncbi Is extended hepatectomy for hepatobiliary malignancy justified?
    Jean Nicolas Vauthey
    Departments of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    Ann Surg 239:722-30; discussion 730-2. 2004
    ..Extended hepatectomy may be required to provide the best chance for cure of hepatobiliary malignancies. However, the procedure may be associated with significant morbidity and mortality...
  62. ncbi Preoperative predictors of survival after resection of small hepatocellular carcinomas
    Jeffrey D Wayne
    International Cooperative Study Group on Hepatocellular Carcinoma: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 235:722-30; discussion 730-1. 2002
    ..In these patients, transplantation and/or ablation should be considered as possible alternative therapies...
  63. ncbi Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston 77030, USA
    Ann Surg Oncol 13:712-20. 2006
    ..Resection should be performed as part of a multidisciplinary approach, because recurrence is common...
  64. ncbi Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis
    Chandrajit P Raut
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas, 77030-4009, USA
    Ann Surg Oncol 12:616-28. 2005
    ..RFA can be performed in these patients with relatively low complication rates. Confirmation of these results in randomized trials should be considered...
  65. ncbi A prospective evaluation of ultrasound-directed transparenchymal vascular control with linear cutting staplers in major hepatic resections
    David L Smith
    Department of Surgical Oncology, 1400 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    Am J Surg 190:23-9. 2005
    ....
  66. ncbi Simplified staging for hepatocellular carcinoma
    Jean Nicolas Vauthey
    International Cooperative Study Group on Hepatocellular Carcinoma, Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 20:1527-36. 2002
    ..The current American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC) fails to stratify patients adequately with respect to prognosis...
  67. ncbi Radiofrequency ablation of hepatic metastases
    Alexander A Parikh
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA
    Semin Oncol 29:168-82. 2002
    ....
  68. ncbi Outcome after curative resection for locally recurrent rectal cancer
    Isabelle Bedrosian
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, Texas 77030, USA
    Dis Colon Rectum 49:175-82. 2006
    ..Preoperative carcinoembryonic antigen and an R0 resection margin were the only significant predictors of overall survival. p53, bcl-2, and ki-67 did not impact survival outcomes...
  69. ncbi Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells
    Paul J Chiao
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 95:1696-705. 2002
    ..Primary hepatocellular carcinoma (HCC) is one of the 10 most common human carcinomas in the world. The mechanism by which HCC cells resist apoptosis induced by various treatment modalities is poorly understood...
  70. ncbi Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
    Martin Palavecino
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Surgery 145:399-405. 2009
    ..Perioperative outcome and survival after major hepatic resection for HCC, with and without PVE, were investigated...
  71. ncbi Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines
    Everett M Stone
    Department of Chemical Engineering, University of Texas, Austin, 78712, USA
    ACS Chem Biol 5:333-42. 2010
    ....
  72. ncbi Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases
    Georges Vlastos
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    Ann Surg Oncol 11:869-74. 2004
    ..Hepatic resection should be considered a component of multimodality treatment of breast cancer in these patients...
  73. ncbi Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer
    Y Z Patt
    Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 7:3375-80. 2001
    ..Therefore, this regimen cannot be recommended for cholangiocarcinoma, but it may have a role in the treatment of gallbladder carcinoma, particularly among patients who were refractory to higher priority investigational agents...
  74. ncbi Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy
    J T Lenert
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Tex. 77030, USA
    Surgery 130:1060-7. 2001
    ..An assumption that the adrenal mass is metastatic disease will be wrong in up to 50% of such patients...
  75. ncbi Cytosolic phospholipase A(2)-mediated ICAM-1 expression is calcium dependent
    C C Barnett
    Department of Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Avenue, Houston, TX 77030, USA
    J Surg Res 99:307-10. 2001
    ..As lipid mediators are known to work via calcium-dependent mechanisms in nearly all mammalian cells, we hypothesize that inflammatory-mediated ICAM-1 upregulation is dependent on both cPLA(2) and intracellular calcium...
  76. ncbi Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors
    S A Curley
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Surg 227:229-35. 1998
    ..We report a unique, previously undescribed multigeneration kindred with von Hippel-Lindau (VHL) disease in whom clinical or genetic screening led to the detection of surgically resectable neoplastic disease in several family members...
  77. ncbi Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene
    S Kagawa
    Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 61:3330-8. 2001
    ..Together, these results suggest that delivering the TRAIL gene to cancerous cells may be an alternative approach to cancer treatment...
  78. ncbi Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies
    Francesco Izzo
    Pascale NAtional Cancer Institute, Naples, Italy
    J Clin Oncol 22:1815-22. 2004
    ..Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with HCC as well as other human tumors auxotrophic for arginine is warranted...
  79. ncbi Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma
    Timothy M Pawlik
    Department of Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Arch Surg 140:450-7; discussion 457-8. 2005
    ..Clinical predictors should not be used to exclude patients from surgical resection because these factors do not reliably predict outcome...
  80. ncbi Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database
    Kelvin K Ng
    Centre for the Study of Liver Disease, Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Ann Surg Oncol 12:364-73. 2005
    ..This study evaluated the long-term outcome of patients with hepatic resection for large (>5 cm in diameter) or multinodular (more than three nodules) HCC by using a multi-institutional database...
  81. ncbi One surgeon's unabashedly biased view on liver resection
    Steven A Curley
    J Clin Oncol 23:8286-8. 2005
  82. ncbi Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note
    Anton J Bilchik
    John Wayne Cancer Institute at St John's Health Center, Santa Monica, CA, USA
    J Clin Oncol 23:9073-8. 2005
  83. ncbi Hepatobiliary cancers. Clinical practice guidelines in oncology
    Al B Benson
    Robert H. Luri Comprehensive Cancer Center of Northwestern University
    J Natl Compr Canc Netw 4:728-50. 2006
  84. ncbi Radiofrequency ablation of primary and metastatic liver tumors
    Steven A Curley
    The University of Texas, Anderson Cancer Center, Houston, USA
    Surg Technol Int 10:99-106. 2002
    ..In the United States, approximately 155,000 new cases of cancer of the liver and bile duct occur annually, with the majority being colorectal metastases...
  85. ncbi Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases
    Francesco Izzo
    The G Pascale National Cancer Institute, Naples, Italy
    Curr Med Res Opin 24:1011-5. 2008
    ..We evaluated this sealant for intraoperative haemostatic effectiveness in an observational series of patients undergoing surgery for the resection of primary and metastatic liver tumours...
  86. ncbi Critical evaluation of the different staging systems for hepatocellular carcinoma (Br J Surg 2004; 91: 400-408)
    Jean-Nicolas Vauthey
    Br J Surg 91:1072. 2004
  87. ncbi Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma
    Isabelle Bedrosian
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Gastrointest Surg 8:56-62; discussion 62-3. 2004
    ..Despite a substantial reduction in tumor volume with neoadjuvant CRT, local excision should be recommended with caution in patients with locally advanced rectal cancer...
  88. ncbi Radiofrequency ablation: the experts weigh in
    Kenneth K Tanabe
    Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 100:641-50. 2004
  89. ncbi Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis
    Timothy M Pawlik
    Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 14:2807-16. 2007
    ..The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown. The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver...
  90. ncbi Comparison of CT methods for determining the fat content of the liver
    Yoshihisa Kodama
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 368, Houston TX 77030, USA
    AJR Am J Roentgenol 188:1307-12. 2007
    ..The purpose of this study was to assess which of a number of methods of measuring attenuation on CT scans is best for prediction of hepatic fat content...
  91. ncbi Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis
    Francesco Izzo
    National Cancer Institute G Pascale Foundation, Naples, Italy
    J Gastroenterol Hepatol 22:86-91. 2007
    ..Reduced extracellular arginine inhibits viral replication through unknown mechanisms. It is hypothesized that ADI-SS PEG 20,000 mw reduces HCV viral titers through nitric oxide (NO)-dependent effects...
  92. ncbi Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis
    Heike Aligayer
    Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Cancer 94:344-51. 2002
    ..These data suggest that Src-specific inhibitors may have a therapeutic role in inhibiting tumor progression and metastasis, and that measurement of Src activity may aid in selection of early stage patients for adjuvant therapy...
  93. ncbi Re: Right hepatic trisectionectomy for hepatobiliary disease: results and an appraisal of its current role
    Jean-Nicolas Vauthey
    Ann Surg 248:138-9; author reply 139-40. 2008